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Strontium-substituted hydroxyapatite (SrHAp) materials are known to actively promote 
bone formation. However, the optimum level of Sr inclusion needed to elicit a physiologically 
relevant response from bone cells is unclear and can vary dependent on the fabrication process 
employed. In this work hydroxyapatite (HAp), SrHAp powders (2, 5 and 10 wt% (i.e., 1, 2 and 5 
at%) with respect to [Sr/(Sr+Ca) ∙100]), were synthesized with the purity and Sr-substitution was 
confined in the range of 1-8 wt% (1-4 at%). All SrHAp samples contained rod-like crystals 
(<106nm in length), which decreased in length with increasing Sr content, and exhibited larger 
flatter crystals (>300nm in length). TEM-EDX confirmed the presence of Sr and maintenance of 
the HAp lattice structure for both types of crystals. Qualitative in vitro evaluation using primary 
human ostesoblast cells (HOBC) cultured in contact with the SrHAp over 28 days showed that the 
presence of Sr (in particular with the highest Sr content) directly promotes the maturation of 
osteoblasts into osteocytes as compared to the response observed for HAp. As these materials 
contain no additives other than Sr, the effects observed here can only be attributed to the 












Effective bone regeneration remains a significant clinical challenge and advantageous 
strategies to enhance bone defect healing are still urgently needed. Hydroxyapatite (HAp) has been 
widely used in the biomedical fields in applications such as implant coatings, fillers for bone 
substitutes and as drug carriers for controlled release. Its widespread application is due to its 
biocompatibility, bioactivity and similarity to bone mineral component [1]. Today bone graft 
materials are expected not only to facilitate the growth of as replacement tissue after disease, 
injury, or failure due to ageing, but also to provide for the delivery of biologically active 
substances, which act against the causative disease of bone loss [2]. Extensive work has been 
carried out on the development of biomaterials combined with components that specifically 
promote bone growth, e.g. growth factors and bone morphogenetic proteins. However, the need 
for high concentrations to maintain a therapeutic efficiency increases costs of the therapy and 
generates serious concerns over long-term complications associated with the high dosages of the 
biological molecules [3]. Thus, the substitution of other more biologically active ions such as  Na+, 
Mg2+, K+, Sr2+, Zn2+, Ba2+, Al3+ etc. for Ca2+ into bone graft materials, including HAp, provides a 
feasible solution for bone defect healing [4]-[6]. Substitutions for PO4
3- and OH- ions are also 
possible, for example silicon (SiO4
4-) and carbonate (CO3
2-) [7]. The advantages of such a strategy 
are lower costs, greater simplicity, higher stability, and more efficacies at low concentrations [8]. 
Strontium (Sr) is a unique biologically active trace element that simultaneously stimulates bone 
formation while inhibiting bone resorption [9]. It has been reported that Sr increases pre-osteoblast 
proliferation, osteoblast differentiation, type I collagen synthesis and bone matrix mineralization 
and inhibits osteoclast differentiation and activation [9], [10].  
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Typically, Sr is found in bone at very low concentrations of between 0.008-0.01 at% but can 
be found at concentrations of between 3 and 7 at% where bone is actively metabolising [7], [11]. 
The latest advances in Sr based regenerative therapies have been reviewed by Jimenez et al [10]. 
Given the positive biological properties of Sr in bone remodelling, it has been used in many studies 
as an additive to various biomaterials, including bioactive glasses [12], [13] and calcium 
phosphates (CaP) [12], [14]. Sr incorporation into different CaP-based biomaterials are highly 
promising for providing appropriate support to a defective site and delivering biologically active 
components to encourage bone tissue regeneration. Moreover, in vivo studies showed that Sr-
doped CaP cements and bioceramic materials promote bone regeneration [15], [16]. Previously, 
the drug strontium ranelate (SrRan) was used to treat osteoporosis, however, it was subsequently 
withdrawn from use in 2017 in Europe due to concerns it increased the chances of myocardial 
infarction in patients [17]. As such, there is a clear need to provide more localised delivery of Sr 
into bone defects, to administer the required therapeutic effect. Further to this, there is still 
disagreement in the literature as to the appropriate (and minimum) concentration of Sr to be 
effective without provoking any negative consequences [18], [19]. 
The aim of this work was to manufacture a range of Sr-substituted HAp materials with 
physiologically relevant levels of Sr and to study their effect on primary human osteoblast cells 
(HOBC). Specifically, the work has focused on low concentrations of Sr substitution of the HAp 
to determine an effective minimum dosage to inform future work. The physicochemical properties 
and level of ionic substitution of each sample were compared using atomic absorption 
spectrometry (AAS), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron 
spectroscopy (XPS), X-ray diffraction (XRD), scanning electron microscopy, energy dispersive 
X-Ray (EDX) analysis and transmission electron microscopy (TEM). Studies have shown that 
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biocompatibility is very dependent on the cell type involved in the tests. This work utilizes primary 
human osteoblasts cells (HOBC) which provide more clinically relevant results and brings the 
translational process closer as the interspecies differences are circumvented [20].  
 
2. Materials and methods 
2.1. Preparation 
HAp powders with 4 different Sr concentrations, namely, pure HAp (HAp), HAp with 2 
wt% Sr in respect to total content of cations, namely, Ca and Sr (2SrHAp), HAp with 5 wt% Sr 
(5SrHAp) and HAp with 10 wt% Sr (10SrHAp) were synthesised via aqueous precipitation 
described in detail previously [21]. Briefly, the main steps are shown in Figure 1. 
The powders were uniaxially pressed at 10 kN into cylindrical moulds using 0.3 g of powder 
per disk (13 mm x 1 mm) and were sintered at 600 oC for 2 h using heating rate at 2 oC/min up to 





Figure 1. The main steps and technological parameters of the HAp powders synthesis. 
 
2.2. Physico-chemical characterization 
Atomic absorption spectrometry (AAS, Varian SpektrAA 880, Australia) was performed 
using electrothermal atomization according to the LVS ISO 11047:1998 standard test method. 
X-ray photoelectron spectroscopy (XPS) was performed using an AXIS Ultra delay-line 
detector (DLD) spectrometer (Kratos, UK). Spectra were analysed using monochromated Al Kα 
X-rays (hѵ=1486.6 eV) operating at 10 kV and 15 mA (150 W). Wide energy survey scans 
(WESS) were recorded at a pass energy of 160 eV. High resolution spectra for C1s, O1s, Ca2p, 
P2p/Sr3d, Sr3p and P2s were recorded at pass energy of 40 eV. A Kratos charge neutraliser system 
was used for all samples. Sample charging effects on the calculated binding energy (BE) positions 
were adjusted by setting the lowest BE component of the C1s spectral envelope to 285.0 eV. 
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Photoelectron spectra were further processed by subtracting a Tougaard background and using the 
peak area for the most intense spectral line of each detected elemental species to determine the 
atomic%. In the case of the Sr-substituted samples, the P2p and Sr3d peaks overlap at 133/134 eV 
therefore, for these samples the P2s and Sr3p peaks were used in order to provide the appropriate 
quantification results. In total 3 areas were analysed from each sample.  
Scanning electron microscopy (SEM) with energy dispersive X-ray (EDX) analysis was 
performed using a Hitachi SU5000 field emission instrument equipped with an X-MaxN 80 mm2 
silicon drift detector (Oxford Instruments, UK). For SEM and EDX analysis, an accelerating 
voltage of 10 kV was used. To make the surface of the samples conductive for the electron 
microscopy, they were coated with a thin layer (20 nm) of Au/Pd (60/40 ratio). The coating was 
performed using an Emitech K500X sputtering deposition with Argon gas. 
Fourier transform infrared (FTIR) spectra were recorded using spectrometer 
(Varian 800 FT-IR, Scimitar Series, USA) in attenuated total reflectance (ATR, GladiATRTM, 
Pike technologies, USA) mode. The FTIR spectra were obtained at 4 cm-1 resolution co-adding 50 
scans over a range of wavenumbers from 400 cm-1 to 4000 cm-1. Before every measurement a 
background spectrum was taken (50 scans) and deducted from the sample spectrum. 
X-Ray diffraction (XRD) analysis were performed using system (X'Pert PRO, PANalytical, 
the Netherlands) operating at 40 KV and 30 mA using a Cu Kα1 radiation (λ=1.5406 Å). Patterns 
were obtained over the range of 2-Theta from 10° to 70° with an angular step interval of 0.0334°. 
The X'Pert Data Viewer and X'Pert HighScore software were used for processing and analyzing 
the XRD data. For the phase identification the International Centre for Diffraction Data (ICDD) 
was used (PDF-2/2005 card #01-072-1243 for HAp). Computer structural analysis of XRD 
diffractograms was performed by the Rietveld method using the software Profex-BGMN-Bundle-
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3.8.0 [22]. Rietveld’s refinement for HAp was done based on data from with the hexagonal space 
group P63/m using PDF card #01-074-0565 as structural model for HAp. Rwp, Rexp and X
2 for 
refinements indicate the quality of the fits. The observed, calculated and differential patterns are 
shown in Figure 2.  
 
Figure 2. Observed (red), calculated (black) and differential (green) patterns for (a) HAp, (b) 
2SrHAp, (c) 5SrHAp and (d) 10SrHAp calcined at 600 oC for 2 h. 
 
Transmission electron microscopy (TEM) observations were made using a JEOL 2100F 
microscope operating at 200 kV bias voltage. The samples for TEM analysis were prepared by 
roughly grinding the sintered disks followed by sonication in ethanol. The sonicated solutions were 
drop-casted on a Cu grid with 3 nm carbon films and the images were recorded using a charged 
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coupled device detector. Scanning transmission electron microscopy-energy dispersive X-ray 
analysis (STEM-EDX) was performed using Oxford instruments X-Max detector coupled with the 
same JOEL 2100F system at 1.5 nm spot size. The STEM images were recorded using a JEOL 
high-angle annular dark field (HAADF) detector. ImageJ software was utilised to measure the 
dimensions of 60 nanocrystals from each sample. The results are reported as the mean ± standard 
deviation (SD). 
2.3. In vitro cell studies 
2.3.1. Cytoskeletal and collagen I 
Primary human osteoblast cells (HOBC) were isolated and characterised using previously 
described method [23]. The SrHAp and HAp control samples were seeded with 2x105 cells/well 
in 1 mL medium (Dulbecco's modified eagle medium (DMEM) + 5% fetal calf serum (FCS), 
Sigma-Aldrich, UK) for 1, 7 and 28 days. Fresh medium was added twice a week. At the pre-
designated time points (1, 7 and 28 days), the cell culture supernatant was removed from the wells 
and samples were gently washed once with phosphate-buffered saline (PBS) without Ca2+ and 
Mg2+ at room temperature. Samples were then fixed with 4% formaldehyde, 2% sucrose solution 
in PBS and incubated for 15 min at 37 °C, 5% CO2 followed by further washing. Fixed samples 
were permeabilized with 0.05% Triton X100 solution (Sigma-Aldrich, UK) for 5 min at 4 °C, 
followed by washing with PBS for 5 min at 37 °C. Samples were incubated with the collagen I 
primary antibody (1:500 dilution with 1% bovine serum albumin (BSA):PBS, Sigma-Aldrich, UK) 
overnight at 4 °C, washed with 0.1% Tween 20 solution (ICN Biomedicals, USA) for 5 min at 
room temperature, followed by incubation with the Rhodamine conjugated goat IgG fraction to 
mouse IgG (Invitrogen, USA) secondary antibody at a concentration of 1 μg/mL in 1% BSA:PBS 
for 1 h at 37 oC. The samples were washed with Tween 20 wash solution and incubated with 
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5 μg/mL Oregon-green phalloidin (Molecular Probes, USA) for 30 min at 4 °C. The samples were 
then placed onto glass slides and mounted with a fluorescence stabilising mounting medium with 
DAPI (Vectashield, Vector Laboratories Inc., UK). The samples were viewed immediately by 
confocal laser scanning microscopy (Zeiss 510, UK). 
 
2.3.2. Alkaline phosphatase enzymatic activity assay 
At each experimental endpoint (1, 7 and 28 days), the supernatant was removed from the 
wells. The cells were washed twice in ice-cold PBS and lysed in 0.1% Triton-X. 100 μL of the 
lysate was transferred to a 96-well plate, 100 μL of para-Nitrophenylphosphate (p-NPP) solution 
was added to the sample, allowed the reaction to take place at 37 °C for 40 min, and then 50 μL of 
3 M NaOH was added to terminate the reaction. The absorbance at 405 nM within 15 min of 
terminating the reaction was read. The values obtained were normalized to the control 
measurements and expressed as a percentage of change from control, i.e., alkaline phosphatase 
(ALP) activity on the HAp samples at day 1. Results are expressed as an average value of the three 
assessments per series of samples ± SD. The differences were tested for statistical significance 
using a one-way ANOVA followed by Tukey post hoc test for multiple comparisons. 
 
3. Results 
3.1. Physico-chemical characterization 
The chemical composition of all the samples was determined using AAS, EDX and XPS. 
The nominal and experimental amounts of Sr measured by AAS were close to the nominal values 
(Table 1). This indicates that no significant Sr losses have occurred during the synthesis. EDX of 
the pressed HAp disk gave a stoichiometry of 1.67 ± 0.02, equivalent to that of pure HAp. The 
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corresponding Ca/P ratios of the Sr-substituted HAp materials were higher than expected, with 
values reported between 1.74 ± 0.01 and 1.76 ± 0.02, as shown in Table 2 and Figure 3. The 
corresponding (Ca+Sr)/P ratios were shown to be slightly higher than the Ca/P ratio, with the 
Sr/(Ca+Sr) atomic ratios increasing with the increasing levels of Sr in the samples. The additional 
EDX peaks correspond to either Au/Pd coating or adventitious carbon on the surface of the samples 
(with peaks at 0.28 KeV (C Kα), 2.12 keV (Au Mα) and 2.83 keV (Pd Lα)). No other impurities 
were detected from the EDX analysis. 
 








Sr/(Ca + Sr) 
Experimental 
Sr/(Ca + Sr) 









HAp - - - - - - - - 
2SrHAp 0.78 9.00 0.56 ± 0.06 6.44 ± 0.69 0.01 0.02 0.01 ± 0.00 0.01 ± 0.00 
5SrHAp 2.07 24.00 1.41 ± 0.14 16.29 ± 1.62 0.02 0.05 0.02 ± 0.01 0.04 ± 0.01 
10SrHAp 4.09 48.00 3.10 ± 0.30 36.15 ± 3.50 0.05 0.10 0.04 ± 0.01 0.08 ± 0.01 
 
Table 2. EDX quantification results from the surfaces of the discs sintered at 600 oC for 2 h. 
Sample Ca/P (Ca+Sr)/P Sr/(Ca+Sr) 
HAp 1.67 ± 0.02 1.67 ± 0.02 -  
2SrHAp 1.75 ± 0.02 1.77 ± 0.02 0.01 ± 0.01 
5SrHAp 1.76 ± 0.02 1.81 ± 0.03 0.02 ± 0.01 






Figure 3. EDX spectra for (a) HAp, (b) 2SrHAp, (c) 5SrHAp, (d) 10SrHAp discs sintered at 600 
oC for 2 h. 
 
Figure 4 show typical XPS WESS for (a) HAp and (b) 10SrHAp. For the HAp sample, all 
the expected peaks for O1s, C1s Ca2p, P2p and P2s were detected, as shown in Table 4. However, 
the Ca/P ratio was slightly lower than the expected 1.67 for stoichiometric HAp, at 1.60 ± 0.03 as 
highlighted in Table 3. For all three Sr-substituted samples, the WESS showed the presence of Sr, 
as evidenced by the Sr3p3/2 peak around 269.0eV (Table 4 and Figures 4(b) for the 10SrHAp 
sample). The corresponding high resolution Sr3p3/2 peaks, as shown in Figures 5(d, g and j) for 
2SrHAp, 5SrHAp and 10SrHAp, respectively, confirm the presence and successful substitution of 
Sr for Ca within each substituted material. No CO3
2- peaks were detected in the C1s spectral 
envelope (typically observed around 289.0-290.0 eV) [24]. The Ca/P ratios for the Sr-substituted 
samples were calculated at 1.44 ± 0.07 for 2SrHAp, 1.41 ± 0.05 for 5SrHAp and 1.29 ± 0.06 for 
10SrHAp (as shown in Table 3), all of which are lower than 1.67 for stoichiometric HAp. As all 
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three Sr-substituted samples contain Sr (as determined by AAS, EDX and XPS), it should be noted 
that the spectral envelope observed around 133.4-133.8 eV comprises an overlap of the Sr3d and 
P2p peaks as the Sr3d5/2 (133 ± 0.5 eV), Sr3d3/2 (135 ± 0.5 eV) and the P2p (132-133 eV) lines are 
positioned very close together. Therefore, in order to quantify the P and Sr at% values in the Sr-
substituted samples, the P2s and Sr3p peaks are used instead of the P2p and Sr3d peaks. The main 
peaks recorded for all Sr-substituted samples shown in Table 4 were therefore Ca2p3/2 (347.5-
347.7 eV), P2s (190.9-190.2 eV), O1s (530.4 eV) and Sr3p3/2 (269.2-269.7 eV).  
The (Ca+Sr)/P ratios for each Sr-substituted sample determined by XPS (see Table 3), are 
as follows: 1.45 ± 0.07 for 2SrHAp, 1.43 ± 0.05 for 5SrHAp and 1.35 ± 0.06 for 10SrHAp. EDX 
analyse approximately 1 µm depth of the disk samples, whereas XPS only analyse the top 5-10 
nm of the disks sample surface [25]. There is a high probability that the total area of analysis in 
XPS and EDS is different which gives rise to the difference in Ca/P and (Ca+Sr)/P ratios observed. 
However, it can be seen that for each sample the ratio is slightly larger for (Ca+Sr)/P in comparison 
to the Ca/P ratios alone, highlighting that for each Sr-substituted sample Sr has been successfully 
substituted for Ca within HAp. The corresponding Sr/(Ca+Sr) ratios found in Table 3 are 
interesting as they show a clear increase in Sr substitution, therefore, 0.01 ± 0.00 for 2SrHAp, 0.02 
± 0.01 for 5SrHAp, and 0.04 ± 0.01 for 10SrHAp. This data indicates that as the amount of Sr is 
increased in the following sequence 2SrHAp→5SrHAp→10SrHAp as highlighted by AAS in 
Table 1 for each Sr-substituted samples, the subsequent percentage ratios of atomic concentration 
also increase accordingly, confirming that as a larger percentage concentration of Sr is added at 
the beginning of the reaction, a larger amount of Sr is substituted for Ca within the SrHAp sample. 
It should be noted that the Sr/(Ca+Sr) values as determined by XPS correlate strongly with the 
Sr/(Ca+Sr) results from the AAS and the EDX, as shown in Table 1 (AAS), Table 2 (EDX) and 
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Table 3 (XPS). No impurities were detected from the XPS analysis. This suggests that the aqueous 
precipitation synthesis employed here successfully substitutes Sr within the HAp lattice as 
amounts of the Sr source are increased.  
 




Figure 5. XPS of (a-c) HAp, (d-f) 2SrHAp, (g-i) 5SrHAp, (j-l) 10SrHAp discs sintered at 600 oC 
for 2 h. 
Table 3. XPS quantification results from the surface of the discs sintered at 600 oC for 2 h. 
Sample Ca/P (Ca+Sr)/P Sr/(Ca+Sr) 
HAp 1.60 ± 0.03 - - 
2SrHAp 1.44 ± 0.07 1.45 ± 0.07 0.01 ± 0.00 
5SrHAp 1.41 ± 0.05 1.43 ± 0.05 0.02 ± 0.01 
10SrHAp 1.29 ± 0.06 1.35 ± 0.06 0.04 ± 0.01 
 
Table 4. Peak positions (eV) as determined by XPS. 
Sample 
Peak Positions – BE (eV) 
C1s O1s Ca2p3/2 P2p/Sr3d5/2 P2s Sr3p3/2 
HAp 285.0 531.4 347.5 133.4 190.9 - 
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2SrHAp 285.0 531.4 347.5 132.8 190.9 269.3 
5SrHAp 285.0 531.4 347.5 133.7 191.0 269.7 
10SrHAp 285.0 531.4 347.7 133.8 191.2 269.2 
 
A typical FTIR spectrum for SrHAp is shown in Figure 6 with absorbance bands at 1090, 
1022, 963, 560, 600 and 472 cm-1 attributed to phosphate [PO4] vibrations and at 3569 and 631 
cm-1 attributed to characteristic [OH] bands [26]. The only difference observed in the spectra was 
that with an increase of Sr content, the intensity of the [OH] groups’ absorption band at 631 cm-1 
decreased. This is in good agreement with previous studies suggesting that substituting Ca2+ ions 
with ionic radius 0.100 nm with larger Sr2+ ions with radius of 0.118 nm results in perturbation of 
the HAp lattice structure [27]. No CO3
2- peaks (typically observed around 1550-1400 cm-1 and 875 
cm-1) were detected in any of the samples from the FTIR analyses [28]. 
 
Figure 6. FTIR spectra of (a) HAp, (b) 2SrHAp, (c) 5SrHAp, (d) 10SrHAp calcined at 600 oC 
for 2 h. 
17 
 
The XRD patterns shown in Figure 7 indicate that regardless of the chemical composition 
all samples had a hexagonal lattice structure with space group P63/m typical to HAp [29]. 
Displacement of the peaks, which according to analogous studies would confirm the incorporation 
of Sr into the HAp structure [30], was observed for all the Sr substituted materials (Table 5). At 
the same time, peaks indicating the presence of other Sr-containing compounds were not detected. 
Slight broadening and merging of peaks as Sr content increases was observed, specifically, for 
peaks (211) and (112). The full width half maximum (FWHM) for the representative peaks are 
shown in Table 6. This is consistent with studies reporting that incorporation of Sr causes 
deformation of the HAp crystalline structure, which leads to a decrease in crystallinity [31]. The 
broadening of the peaks can also be a consequence of nano-sized crystals, i.e. reduction of the 
crystallite size [32]. Although the broadening and shift in the peak positions are very small, they 




Figure 7. XRD patterns of (a) HAp, (b) 2SrHAp, (c) 5SrHAp, (d) 10SrHAp calcined at 600 oC 
for 2 h. 
Table 5. 2θ Position (degrees) values for the peaks of various samples. 
Plane HAp 2SrHAp 5SrHAp 10SrHAp 
(002) 25.8961 25.8938 25.8839 25.8615 
(211) 31.7668 31.7560 31.7530 31.7323 
(130) 39.7873 39.7727 39.7520 39.7296 
(222) 46.7074 46.6946 46.6795 46.6298 
 
Table 6. FWHM (in degrees) values for the peaks of various samples as determined from the 
TEM analyses. 
Plane 2θ (degrees) HAp 2SrHAp 5SrHAp 10SrHAp 
(002) 25.8 0.2446 0.2540 0.2602 0.2660 
(211) 31.7 0.4698 0.5045 0.5527 0.5739 
(130) 39.7 0.5014 0.5393 0.5944 0.6021 
(222) 46.7 0.4342 0.4435 0.4522 0.4634 
 
The above observations regarding changes in crystallite size with increasing Sr content were 
confirmed by Rietveld analysis. Refined lattice parameters, crystallite size and R-values obtained 
for all samples are listed in Table 7. The low R-values confirm the successful and reliable 
performed refinements. The c and a axis parameters values show little effect with the different Sr 
content, i.e. slightly increases with increasing Sr content suggesting the larger radius ions entered 
the apatite lattice and induced the hexagonal lattice expansion. This is in a good agreement with 
the results obtained by Chen et al. [33]. All the samples have larger crystallite size along the [001] 
plane compared to that along the [100] plane, irrespective of the Sr content. In general, the size of 
crystallites decreases by increasing the Sr content in the hexagonal HAp structure. 
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Table 7. Lattice parameters and R-values for HAp and SrHAp samples obtained by 
Rietveld refinement. 
 HAp 2SrHAp 5SrHAp 10SrHAp 
Lattice parameters (Å) 
a 9.42854 9.43273 9.43623 9.44355 
c 6.88281 6.88329 6.88650 6.89267 
Crystallite size (nm) 
[001] 60.30 ± 2.50 61.60 ± 2.70 56.40 ± 2.20 56.20 ± 2.50 
[100] 24.64 ± 0.37 22.98 ± 0.31 21.88 ± 0.28 19.82 ± 0.29 
R-Values (%) 
Rexp (%) 2.44 2.38 2.36 2.27 
Rwp (%) 3.20 3.23 3.18 3.07 
X2 1.72 1.84 1.82 1.83 
 
The high-resolution TEM images shown in Figure 8 indicate that the average length of the 
HAp crystals is 106 ± 23 nm, with crystals measuring from 69 to 168 nm. In comparison, the 
average length of the Sr-substituted materials is on the nanoscale, with values reported for the 
2SrHAp of 82 ± 22 nm (range of 44-157 nm), 5SrHAp of 67 ± 16 nm (range of 32-115 nm) and 
10SrHAp of 51 ± 11 nm (range of 28-88 nm). This decrease in the dimensions of the measured 
crystals with increasing Sr content would be in line with expectations, as Sr substitution of HAp 
inhibits crystal growth [34]. This is in accordance with the XRD observations where the 
broadening increases with the increased levels of Sr substitution. Further to this, for all the Sr-
substituted samples, larger flatter crystals of varying dimensions are observed (typically up to 300 
nm in length), which are not seen in the HAp sample. The SEM micrographs of the surface of the 
HAp and SrHAp disks corroborated the results of the TEM, as shown in Figure 9. Two distinct 
morphologies were observed, with predominantly small rod-like features observed for the HAp, 
with larger flatter features clearly shown for the 2SrHAp, 5SrHAp and 10SrHAp disk sample 
surfaces, as shown in Figures 9(b-d), respectively. In addition, as the Sr content increased, the 
amount of the larger flatter particles increased. Based on analogous studies, this could indicate that 
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non-miscible phases of Ca-rich HAp and Sr-rich HAp have formed [35], [36]. However, the in-
depth STEM-EDX (as shown in Figure 10) and TEM (Figure 11) analysis confirmed the presence 
of Sr in both the rod-like crystals and the larger flatter crystals. STEM-EDX mapping of the 
distribution of Ca, P, O and Sr highlighted that these elements were homogeneously distributed 
across both the rod-like and larger flatter crystals, as observed in Figure 10(a). As shown in Figure 
10(b), the peak ratio of Sr/Ca for both rod-shaped and flatter crystals were very similar indicating 
no major change in the Sr ratio in the two types of crystallites. 
 
Figure 8. TEM micrographs of (a) HAp, (b) 2SrHAp, (c) 5SrHAp, (d) 10SrHAp calcined at 600 




Figure 9. SEM surface micrographs of (a) HAp, (b) 2SrHAp, (c) 5SrHAp, (d) 10SrHAp discs 
sintered at 600 oC for 2 h. 
 
Further detailed analyses of the TEM results clearly highlights that for the SrHAp samples 
both the rod-like crystals and flatter larger crystals observed (as shown in Figure 11) have lattice 
spacings corresponding to the (002) plane of HAp. This indicates that the flat regions, although 
not observed in pure HAp samples, have maintained the native lattice structure even upon the 
substitution of Ca2+ with Sr2+. This concurs with the STEM-EDX observations highlighted in 
Figure 10. The selected area electron diffraction (SAED) patterns from the TEM analyses (Figure 
12) show the different planes of the HAp and 10SrHAp samples, which correspond to those 




Figure 10. (a) STEM-EDX results of 10SrHAp calcined at 600 oC for 2 h showing the presence 






Figure 11. TEM image (left - scale bar 50 nm) and corresponding high-resolution TEM image 
(right - scale bar 2 nm) from 10SrHAp samples. 
 
 
Figure 12. SAED pattern from (left) HAp and (right) 10SrHAp. The diffraction rings 






3.2. In vitro characterization 
Qualitative in vitro evaluation (Figure 13) showed that throughout the test period all SrHAp 
samples maintained viable cell adhesion throughout the 28-day test period and were positive for 
collagen I at day 1, which increased by day 28. The HAp control sample supported minimal viable 
cell adhesion and, viable cells were not observed by day 28. In addition to positive collagen I 
staining, cells cultured in contact with the 2SrHAp, 5SrHAp and 10SrHAp materials demonstrated 
a high level of actin fibre organisation by day 28 and an enhanced expression of collagen I 
compared to earlier time points, with a denser and more organised expression observed for the 
10SrHAp sample compared to other samples in the series (or HAp), as shown in Figure 13. 
Moreover, the reorganisation of the matrix as the osteoblast becomes an osteocyte is signalled by 





Figure 13. Qualitative immunohistochemistry for collagen I, when cells were cultured in contact 
with HAp, 2SrHAp, 5SrHAp and 10SrHAp discs sintered at 600 oC for 2 h (samples were 




Figure 14. ALP activity of HOBC cultured in contact with HAp (control), 2SrHAp, 5SrHAp and 
10SrHAp samples at 1, 7 and 28 days. *: p<0.05 compared to 10SrHAp at day 1; $: p<0.05, 
$$$:<0.001 compared to 10SrHAp at day 7; £: p<0.05 compared to 10SrHAp at day 28. 
 
4. Discussion 
A range of SrHAp powders with nominal compositions comprising 1, 2 and 5 at% Sr (with 
respect to [Sr/(Sr+Ca)]∙100]) and a pure HAp control have been synthesised using an aqueous 
precipitation method. Characterisation using AAS, FTIR, XRD, SEM/EDX, STEM/EDX and XPS 
showed the actual Sr contributions to be 0.56 ± 0.06, 1.41 ± 0.14 and 3.10 ± 0.30 wt% (6.44 ± 
0.69, 16.29 ± 1.62 and 36.15 ± 3.50 at%), respectively. The stoichiometry of the SrHAp samples 
and HAp control were 1.67 ± 0.02 and 1.60 ± 0.03, as determined by EDX and XPS, respectively. 
SEM and TEM indicate the formation of rod-like crystals of average length 106 ± 23 nm in all 
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samples with the SrHAp samples also having flat crystals of 300 nm in length. The dimensions 
reported in this study are similar to those observed in previous work using an aqueous precipitation 
approach [32], [34]. Furthermore, the HAp material did not have any impurity phases or CO3
2- 
substitutions (corroborated by FTIR and XPS analyses), corresponding to a chemical formula of 
Ca10(PO4)6(OH)2, as would have been expected. By comparison, the SrHAp samples all showed 
the presence of levels of Sr-substitution that were significantly lower that the nominal values, as 
highlighted by the EDX and XPS results. The EDX also highlighted higher than expected Ca/P 
and (Ca+Sr)/P ratios (>1.67), whereas the XPS showed Ca/P and (Ca+Sr)/P ratios lower than 
expected (<1.67). However, it should be noted that XPS is a surface analysis technique and only 
obtains information from the top 5-10 nm of any sample, whereas EDX in this case was analysing 
over 1 µm into the sample [25]. As such, it is suggested here that the material in the uppermost 
surface of the samples is non-stoichiometric (with a lower set of Ca/P and Ca+Sr/P ratios) and 
differs from the bulk of the disks, which obviously show non-stoichiometry with higher than 
expected Ca/P and (Ca+Sr)/P ratios. However, the differences here could be attributed to 
experimental error within both the EDX and XPS techniques, which can be as much as 10% in 
each case. Despite this, the Sr/(Ca+Sr) ratios, observed in both the EDX and XPS results were in 
complete agreement, highlighting that the Sr levels increases from 2SrHAp→5SrHAp→10SrHAp, 
as expected. Notably, the FWHM of the XRD peaks are seen to increase slightly with increasing 
levels of Sr (and are less well resolved), which indicates that the Sr-substituted materials are 
nanosized, as observed in previous work [32], [34]. These results are corroborated by the TEM 
analyses, showing the decrease in size of the crystallites with increasing Sr substitution in the 
samples. Previous research has highlighted that nanoscale HAp also has improved sintering and 
thermal densification properties, due to its increased surface area, which may improve its 
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mechanical performance [38], [39]. Larger flatter crystals were also observed in the TEM results 
for the SrHAp samples, similar to those observed previously by Bigi et al. [36]. However, further 
analysis utilised STEM/EDX of the SrHAp samples (both the rod-like crystals and the larger flatter 
crystals show the presence of Sr in both crystal types). Further to this, the XRD results show a 
small shift to lower 2𝜃 values, which is indicative of larger Sr2+ ions substituting for Ca2+ in the 
HAp lattice [21], [40], [41]. This is corroborated by the dehydroxylation observed in the FTIR 
spectra and the Ca/P, (Ca+Sr)/P and Sr/(Ca+Sr) ratios observed in the AAS, EDX and XPS results. 
Therefore it would be suggested that the SrHAp samples manufactured here have the chemical 
formula Ca10-xSrx(PO4)6(OH)2. The purity and crystallinity of the SrHAp materials were largely as 
expected and confirmed the presence of low levels of Sr-substitution within the HAp lattice, as 
intended. 
The higher ALP activity for 10SrHAp samples at earlier time points, i.e., 1 and 7 days, and 
significant reduction at 28 days suggest that osteoblasts are starting to form osteocytes by 28 days. 
This phenomenon, when Sr promotes the ultimate differentiation of human osteoblasts into 
osteocytes has previously been observed in a study with SrRan, an approved antiosteoporotic drug 
and is in line with the morphological changes observed [42]. ALP would be recognised as an early 
marker for osteogenic differentiation [43], as would collagen I [17]. Collagen I is an important 
initial bone matrix protein in new bone formation, and as shown here, the 10SrHAp sample has 
enhanced expression of collagen I, clearly undergoing significant reorganisation at 28 days. 
Indeed, Sr has been shown previously to increase collagen synthesis, without affecting matrix 
mineralisation, and the results obtained here for the 10SrHAp sample exhibit this phenomenon of 
increased collagen synthesis at 28 days [44]. Other reports in the literature also point out that 
although Sr has a positive effect on osteoblasts in vitro, it can inhibit mineralisation (by inhibiting 
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crystal growth, enhancing the SrHAp solubility and disturbing Ca metabolism) [44], [45]. 
Interestingly in this study, with increasing Sr content, the SrHAp samples exhibited on average 
smaller nanocrystals (as shown in the TEM results), which would be in line with these 
expectations. However, in this in vitro study we would not have expected the HOBC to mineralise 
[44]. It is obvious that the 10SrHAp sample here exhibited the more positive in vitro response with 
respect to the ALP expression at the earlier time-points of 1 and 7 days, along with enhanced 
collagen expression and matrix re-organisation at 28 days. The AAS, EDX and XPS results 
showed that this sample had the highest level of Sr substitution in the HAp lattice, also exhibiting 
the lowest Ca/P and (Ca+Sr)/P ratio in the uppermost surface of the disks, which may have 
facilitated enhanced dissolution of Sr into the surrounding media, resulting in the potential 
maturation of the osteoblasts into osteocytes. Further to this, as the crystal size decreases, so does 
the potential surface area, which facilitates enhanced dissolution of the materials. It is well 
documented that increased Sr substitution in the HAp lattice facilitates increased dissolution of the 
material [32], [34], and all the results here clearly show that this is optimised in the 10SrHAp 
sample. Importantly, as Sr content is the only variable between samples (given the phase purity 
and lack of other apparent ionic substitutions (namely CO3
2-)), the effects observed here can be 
attributed to Sr alone, which is a unique observation in the literature. 
5. Conclusions 
Hydroxyapatite with varying low levels of Sr substitution was synthesized and 
comprehensively characterized in order to evaluate the effect of these Sr concentrations on the 
physicochemical properties and interaction with primary human osteoblast cells. The results 
obtained clearly show the successful substitution of Ca2+ with Sr2+ ions in the hydroxyapatite 
lattice with levels significantly less than the nominal values. This has created a range of Sr-
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substituted hydroxyapatite materials with no other obvious impurities. In vitro results show that 
the samples with the highest actual Sr concentration have the highest early expression of alkaline 
phosphatase (days 1 and 7) and an enhanced expression of collagen I up to 28 days, clearly 
indicating the maturation of osteoblast cells into osteocytes indicative of the formation of new 
bone. Clearly the level of Sr substitution here is the discriminating factor that is driving the 
differentiation process of the osteoblasts. As such, these findings contribute to a better 
understanding of how the physicochemical properties Sr-substituted hydroxyapatite materials 
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